{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:50:02Z","timestamp":1790653802637,"version":"4.1.0"},"reference-count":28,"publisher":"Korean Cancer Association","issue":"3","license":[{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2021,7,15]]},"abstract":"<jats:p>Purpose We aimed to investigate the prognostic value of serum \u03b22-microglobulin for patients with Burkitt lymphoma (BL) and to propose a risk-stratifying classification system.Materials and Methods A prospective registry-based cohort study of BL patients treated with dose-intensive or effective dose-adjusted chemotherapies (n=81) was conducted. Survival outcomes were compared based on previously reported risk groups and\/or serum \u03b22-microglobulin levels. A risk-stratifying classification system incorporating serum \u03b22-microglobulin levels was proposed and validated in an independent validation cohort (n=60).Results The median age was 47 years, and 57 patients (70.4%) were male. Patients with high serum \u03b22-microglobulin levels (&gt; 2 mg\/L) had significantly worse progression-free survival (PFS) and overall survival (OS) (p &lt; 0.01 for both). Serum \u03b22-microglobulin levels further stratified patients in the low-risk and high-risk groups in terms of PFS (p=0.010 and p=0.044, respectively) and OS (p=0.014 and p=0.026, respectively). Multivariate analyses revealed that a high serum \u03b22-microglobulin level (&gt; 2 mg\/L) was independently associated with a shorter PFS (hazards ratio [HR], 3.56; p=0.047) and OS (HR, 4.66; p=0.043). The new classification system incorporating the serum \u03b22-microglobulin level allowed the stratification of patients into three distinct risk subgroups with 5-year OS rates of 100%, 89.5%, and 62.5%. In an independent cohort of BL, the system was validated by stratifying patients with different survival outcomes.Conclusion Serum \u03b22-microglobulin level is an independent prognostic factor for BL patients. The proposed \u03b22-microglobulin\u2013based classification system could stratify patients with distinct survival outcomes, which may help define appropriate treatment approaches for individual patients.<\/jats:p>","DOI":"10.4143\/crt.2020.1060","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T02:27:08Z","timestamp":1608604028000},"page":"847-856","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum \u03b22-microglobulin Levels"],"prefix":"10.4143","volume":"53","author":[{"given":"Hyung-Don","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungwoo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoungmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Sik","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooryung","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sook","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok-Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hyeh","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.341"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-019-0733-7"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-011-1134-6"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1531-1"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.593274"},{"key":"ref6","first-page":"374","volume-title":"Burkitt lymphoma in the modern era: real world outcomes and prognostication across 30 US cancer centers","author":"Evens","year":"2021"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16425"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28264"},{"key":"ref9","first-page":"2465","volume-title":"Adult Burkitt\u2019s and Burkitt-like non-Hodgkin\u2019s lymphoma: outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation","author":"Sweetenham","year":"1996"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-145128"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00303"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10998"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2015-2"},{"key":"ref14","first-page":"688","volume-title":"Prognostic impact of beta(2)-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma","author":"Yoo","year":"2015"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.144"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2001.19.20.4014"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1308392"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0729-3"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.21.3991"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.07.155"},{"key":"ref23","first-page":"701","volume-title":"The prognostic significance of beta(2)-microglobulin in patients with Hodgkin\u2019s lymphoma","author":"Vassilakopoulos","year":"2002"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.2267"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850515)55"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf253"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20143"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.8.618"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2020-1060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2020.1060","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2020-1060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:43:32Z","timestamp":1626655412000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2020.1060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2020.1060","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]},"assertion":[{"value":"2020-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-17","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}